Cancer Therapy

Company files IND with U.S. FDA for T-cell clinical trials

Published in Medical Letter on the CDC and FDA, January 2nd, 2005

Stem-cell biotechnology and immunotherapy company CyGenics, Ltd., (CYN) announced that it had filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA).

This IND filing is for its phase I/II clinical trials, using T cells produced in its T-cell growth platform, to restore the damaged immune systems of patients. The phase I/II trials will specifically examine the safety and potential efficacy of this growth platform in reconstituting the immune system of patients with certain cancers of the blood system.

This filing follows on from the announcement made on November 18, 2004, on CyGenics' collaboration with Cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-01-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry